Characteristic | Etanercept (N=41) | Prednisone (N=40) |
---|---|---|
Age, mean (SD) | 69.0 (8.6) | 65.1 (9.7) |
Women, n (%) | 13 (31.7%) | 17 (42.5%) |
White race (%) | 97.6 | 100 |
BMI (kg/m2), mean (SD) | 26.6 (7.0) | 26.6 (7.3) |
Current smoker (%) | 19.5 | 27.5 |
Pack-year history, mean (SD) | 50.0 (29.0) | 45.7 (27.6) |
Years of chronic dyspnea, mean (SD) | 11.2 (7.9) | 13.0 (11.5) |
Presenting symptoms (%) | ||
Increased dyspnoea | 95.0 | 90.0 |
Increased cough | 82.9 | 87.5 |
Increased sputum volume | 82.9 | 75.0 |
Increased sputum purulence | 70.7 | 75.0 |
Admitted to hospital for initial treatment of AECOPD, n (%) | 1 (2.4%) | 6 (15%) |
Lung function at randomisation | ||
FEV1 (l), mean (SD) | 0.97 (0.50) | 0.90 (0.44) |
FEV1 (% predicted), mean (SD) | 35.7 (15.8) | 33.1 (11.6) |
FVC (l), mean (SD) | 2.42 (1.02) | 2.23 (0.97) |
FVC (% predicted), mean (SD) | 68.7 (21.6) | 64.6 (20.1) |
Baseline Dyspnoea Index score | 4.85 (2.47) | 4.75 (1.88) |
Comorbid illnesses (%) | ||
Diabetes | 12.2 | 15.0 |
Coronary artery disease | 12.2 | 27.5 |
Congestive heart failure | 2.4 | 2.5 |
Cancer | 7.7 | 5.0 |
Concomitant medications (%) | ||
Home oxygen | 14.6 | 15.4 |
Long-acting anticholinergics | 90.2 | 87.2 |
Inhaled steroid/long-acting β-agonist combination medication | 92.7 | 97.4 |
Long-acting β-agonist | 7.3 | 0 |
Inhaled steroid | 7.3 | 0 |
Theophylline | 17.0 | 10.3 |
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.